Emmaus Life Sciences Inc - Company Profile
Powered by 
All the sales intelligence you need on Emmaus Life Sciences Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Emmaus Life Sciences Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Emmaus Life Sciences Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Emmaus Life Sciences Inc (Emmaus) is a biopharmaceutical company. It is involved in the discovery, development, marketing and sale of innovative treatments and therapies, primarily for rare and orphan diseases and is primarily focusing on its product development efforts in Sickle Cell Disease, a genetic disorder. The company's commercial product, Endari, is an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has established several collaborative relationships for commercialization and distribution of its product to selected pharmacies and hospitals. Emmaus is headquartered in Torrance, California, the US.
Headquarters
United States of America
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, California, 90503
Website
www.emmausmedical.com
Telephone
1 310 2140065
No of Employees
32
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EMMA (OTC)
Revenue (2024)
$12.5M
-25.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-16.1%
(2024 vs 2023)
Market Cap*
$910,000
Net Profit Margin (2024)
XYZ
-55.3%
(2024 vs 2023)
* As of and is in US$
Emmaus Life Sciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | Endari |
| L-Glutamine Oral Powder |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In February, the company received marketing authorization from the Puerto Rico Department of Health for Endari (L-glutamine oral powder). |
| 2023 | Financing Agreements | In May, the company invested US$2.001 million in CellSeed Inc. |
| 2022 | Regulatory Approval | In December, the company received regulatory approval for the marketing of Endari from Kuwaiti Marketing Authorization. |
Competitor Comparison
| Key Parameters | Emmaus Life Sciences Inc | Vertex Pharmaceuticals Inc | Teladoc Health Inc | ANI Pharmaceuticals Inc | Genetix Biotherapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Torrance | Boston | New York | Baudette | Somerville |
| State/Province | California | Massachusetts | New York | Minnesota | Massachusetts |
| No. of Employees | 32 | 6,400 | 5,600 | 970 | 248 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Willis C. Lee | Chairman; Chief Executive Officer | Executive Board | 2024 | 66 |
| Hiroko Huynh | Chief Accounting Officer | Senior Management | 2025 | 47 |
| Charles W. Stark | Chief Science Officer; Senior Vice President - Medical Affairs, Clinical, Regulatory | Senior Management | 2023 | 71 |
| Dale E. Short | Legal Consultant; Secretary | Senior Management | 2018 | - |
| Wei Peu Zen | Director | Non Executive Board | 2019 | 74 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer